Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin

Cancer Cell

Volumn 10, Issue 2, 2006, Pages 159-170

  Phung, Thuy L ^a   Ziv, Keren ^b   Dabydeen, Donnette ^a   Eyiah Mensah, Godfred ^a   Riveros, Marcela ^a   Perruzzi, Carole ^a   Sun, Jingfang ^a   Monahan Earley, Rita A ^a   Shiojima, Ichiro ^c   Nagy, Janice A ^a   Lin, Michelle I ^d   Walsh, Kenneth ^c   Dvorak, Ann M ^a   Briscoe, David M ^a   Neeman, Michal ^b   Sessa, William C ^d   Dvorak, Harold F ^a   Benjamin, Laura E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE; HUMDISEASE

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RAPAMYCIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; EDEMA; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR TUMOR;

EID: 33746800144     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.07.003     Document Type: Article

References (58)

1. Ackah E., Yu J., Zoellner S., Iwakiri Y., Skurk C., Shibata R., Ouchi N., Easton R.M., Galasso G., Birnbaum M.J., et al. Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115 (2005) 2119-2127
2. Baluk P., and McDonald D.M. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am. J. Physiol. 266 (1994) L461-L468
3. Baluk P., Morikawa S., Haskell A., Mancuso M., and McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163 (2003) 1801-1815
4. Benjamin L.E., and Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA 94 (1997) 8761-8766
5. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103 (1999) 159-165
6. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
7. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
8. Bucci M., Gratton J.P., Rudic R.D., Acevedo L., Roviezzo F., Cirino G., and Sessa W.C. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6 (2000) 1362-1367
9. Bucci M., Roviezzo F., Posadas I., Yu J., Parente L., Sessa W.C., Ignarro L.J., and Cirino G. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 904-908
10. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
11. Chen W.S., Xu P.Z., Gottlob K., Chen M.L., Sokol K., Shiyanova T., Roninson I., Weng W., Suzuki R., Tobe K., et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15 (2001) 2203-2208
12. Chen J., De S., Damron D.S., Chen W.S., Hay N., and Byzova T.V. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 104 (2004) 1703-1710
13. Chen J., Somanath P.R., Razorenova O., Chen W.S., Hay N., Bornstein P., and Byzova T.V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 11 (2005) 1188-1196
14. Cho H., Mu J., Kim J.K., Thorvaldsen J.L., Chu Q., Crenshaw III E.B., Kaestner K.H., Bartolomei M.S., Shulman G.I., and Birnbaum M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001) 1728-1731
15. Cho H., Thorvaldsen J.L., Chu Q., Feng F., and Birnbaum M.J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276 (2001) 38349-38352
16. Dafni H., Israely T., Bhujwalla Z.M., Benjamin L.E., and Neeman M. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. Cancer Res. 62 (2002) 6731-6739
17. Dimmeler S., and Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ. Res. 86 (2000) 4-5
18. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
19. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., Goelman G., and Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21 (2002) 1939-1947
20. Dvorak H.F. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog. Clin. Biol. Res. 354A (1990) 317-330
21. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
22. Dvorak H.F. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am. J. Pathol. 162 (2003) 1747-1757
23. Dvorak A.M., Kohn S., Morgan E.S., Fox P., Nagy J.A., and Dvorak H.F. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 59 (1996) 100-115
24. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
25. Edinger A.L., Linardic C.M., Chiang G.G., Thompson C.B., and Abraham R.T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63 (2003) 8451-8460
26. Feng D., Nagy J.A., Hipp J., Dvorak H.F., and Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 183 (1996) 1981-1986
27. Feng D., Nagy J.A., Pyne K., Hammel I., Dvorak H.F., and Dvorak A.M. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6 (1999) 23-44
28. Feng D., Nagy J.A., Brekken R.A., Pettersson A., Manseau E.J., Pyne K., Mulligan R., Thorpe P.E., Dvorak H.F., and Dvorak A.M. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J. Histochem. Cytochem. 48 (2000) 545-556
29. Feng D., Nagy J.A., Dvorak A.M., and Dvorak H.F. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc. Res. 59 (2000) 24-37
30. Fujio Y., and Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274 (1999) 16349-16354
31. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., Buerk D.G., Huang P.L., and Jain R.K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA 98 (2001) 2604-2609
32. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., and Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
33. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., and Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273 (1998) 30336-30343
34. Gratton J.P., Lin M.I., Yu J., Weiss E.D., Jiang Z.L., Fairchild T.A., Iwakiri Y., Groszmann R., Claffey K.P., Cheng Y.C., and Sessa W.C. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4 (2003) 31-39
35. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
36. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
37. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
38. Kamba T., Tam B.Y., Hashizume H., Haskell A., Sennino B., Mancuso M.R., Norberg S.M., O'Brien S.M., Davis R.B., Gowen L.C., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290 (2005) H560-H576
39. Kisucka J., Butterfield C.E., Duda D.G., Eichenberger S.C., Saffaripour S., Ware J., Ruggeri Z.M., Jain R.K., Folkman J., and Wagner D.D. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl. Acad. Sci. USA 103 (2006) 855-860
40. Liu W., Ahmad S.A., Reinmuth N., Shaheen R.M., Jung Y.D., Fan F., and Ellis L.M. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5 (2000) 323-328
41. McDonald D.M., and Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 62 (2002) 5381-5385
42. Meier-Kriesche H.U., and Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin. Ther. 22 Suppl B (2000) B93-B100
43. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., and McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160 (2002) 985-1000
44. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., Lawitts J.A., Benjamin L., Tan X., Manseau E.J., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196 (2002) 1497-1506
45. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
46. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., McDonald D.M., and Blau H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 113 (2004) 516-527
47. Pal S., Datta K., and Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61 (2001) 6952-6957
48. Pettersson A., Nagy J.A., Brown L.F., Sundberg C., Morgan E., Jungles S., Carter R., Krieger J.E., Manseau E.J., Harvey V.S., et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80 (2000) 99-115
49. Rak J., and Kerbel R.S. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol. 333 (2001) 267-283
50. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., and Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14 (1995) 263-277
51. Richard L., Velasco P., and Detmar M. A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp. Cell Res. 240 (1998) 1-6
52. Sarbassov dos D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
53. Sarbassov dos D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
54. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
55. Six I., Kureishi Y., Luo Z., and Walsh K. Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett. 532 (2002) 67-69
56. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., Ranieri E., Gesualdo L., Schena F.P., and Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 352 (2005) 1317-1323
57. Sun J.F., Phung T., Shiojima I., Felske T., Upalakalin J.N., Feng D., Kornaga T., Dor T., Dvorak A.M., Walsh K., and Benjamin L.E. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc. Natl. Acad. Sci. USA 102 (2005) 128-133
58. Sundberg C., Nagy J.A., Brown L.F., Feng D., Eckelhoefer I.A., Manseau E.J., Dvorak A.M., and Dvorak H.F. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am. J. Pathol. 158 (2001) 1145-1160